PMID- 29503579
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220316
IS  - 1178-7090 (Print)
IS  - 1178-7090 (Electronic)
IS  - 1178-7090 (Linking)
VI  - 11
DP  - 2018
TI  - A randomized study of the efficacy and safety of parecoxib for the treatment of 
      pain following total knee arthroplasty in Korean patients.
PG  - 427-433
LID - 10.2147/JPR.S147481 [doi]
AB  - PURPOSE: Parecoxib is an injectable cyclooxygenase-2 inhibitor with proven 
      postoperative analgesic efficacy in a variety of settings, including total knee 
      arthroplasty (TKA). The effect of ethnicity on the efficacy of parecoxib for 
      post-TKA pain has not been studied. PATIENTS AND METHODS: This was a 
      parallel-group, double-blind, randomized, placebo- controlled study of ethnically 
      Korean patients aged >/=18 years who had unilateral TKA. Patients who reported 
      moderate or severe pain 6 hours after the end of postoperative opioid analgesia 
      were randomized to receive a single intravenous dose of parecoxib sodium 40 mg or 
      placebo. Patients were evaluated for 24 hours postdose. The primary efficacy 
      endpoints included time-specific pain intensity difference (PID), time-specific 
      pain relief (PR), and time to rescue medication. The incidence and nature of 
      adverse events (AEs) assessed safety. RESULTS: Of the 116 patients randomized, 58 
      received parecoxib and 58 placebo. Mean (SD) PID was significantly greater for 
      parecoxib vs placebo 1 hour postdose (0.69 [0.67] vs 0.40 [0.59], respectively; 
      p<0.05), and for each time point up to 24 hours. Similarly, mean (SD) PR was 
      significantly greater for parecoxib vs placebo 1.5 hours postdose (1.63 [0.85] vs 
      1.07 [0.90], respectively; p=0.001), and for each time point up to 24 hours. The 
      median time (hours:minutes) to rescue medication was significantly longer for 
      parecoxib vs placebo (21:30 vs 4:08, respectively; p<0.001). Generally, fewer AEs 
      were reported with parecoxib than placebo, and the AE profile was consistent with 
      previous studies. These results are comparable to the findings from a similarly 
      designed study in a Caucasian patient population. CONCLUSION: Parecoxib 40 mg 
      significantly improved postoperative pain vs placebo in Korean patients after 
      TKA. The efficacy and safety of parecoxib in Korean patients is similar to that 
      seen in Caucasian patients.
FAU - Essex, Margaret Noyes
AU  - Essex MN
AD  - Pfizer Inc., New York, NY, USA.
FAU - Choi, Hee-Youn
AU  - Choi HY
AD  - Pfizer Pharmaceutical Korea Ltd, Seoul, South Korea.
FAU - Bhadra Brown, Pritha
AU  - Bhadra Brown P
AD  - Pfizer Inc., New York, NY, USA.
FAU - Cheung, Raymond
AU  - Cheung R
AD  - Pfizer Inc., New York, NY, USA.
LA  - eng
PT  - Journal Article
DEP - 20180223
PL  - New Zealand
TA  - J Pain Res
JT  - Journal of pain research
JID - 101540514
PMC - PMC5827681
OTO - NOTNLM
OT  - COX-2 inhibitor
OT  - parecoxib
OT  - total knee arthroplasty
COIS- Disclosure All authors of this study are full-time employees of, and hold stock 
      in, Pfizer Inc. The authors report no other conflicts of interest in this work.
EDAT- 2018/03/06 06:00
MHDA- 2018/03/06 06:01
PMCR- 2018/02/23
CRDT- 2018/03/06 06:00
PHST- 2018/03/06 06:00 [entrez]
PHST- 2018/03/06 06:00 [pubmed]
PHST- 2018/03/06 06:01 [medline]
PHST- 2018/02/23 00:00 [pmc-release]
AID - jpr-11-427 [pii]
AID - 10.2147/JPR.S147481 [doi]
PST - epublish
SO  - J Pain Res. 2018 Feb 23;11:427-433. doi: 10.2147/JPR.S147481. eCollection 2018.